Many studies have shown that the efficacy and risk of side effects of drug treatment is
influenced by genetic variants. Evidence based guidelines are essential for implementing …

Pharmacogenomics can enhance patient care by enabling treatments tailored to genetic
make-up and lowering risk of serious adverse events. As of June 2019, there are 132 …

Genetic medicine is one of the key components of personalized medicine, but adoption in
clinical practice is still limited. To understand potential barriers and provider attitudes, we …

The clinical implementation of pharmacogenetic biomarkers continues to grow as new
genetic variants associated with drug outcomes are discovered and validated. The number …

Pharmacogenomics (PGx) relates to the study of genetic factors determining variability in
drug response. Implementing PGx testing in paediatric patients can enhance drug safety …

Objective: To review the prevalence, mechanisms, clinical presentation, risk factors and
implications of platinum-induced ototoxicity in paediatric cancer patients based on published …

Cisplatin is a first-line chemotherapeutic agent in the treatment of malignant tumors with
remarkable clinical effects and low cost. However, the ototoxicity and neurotoxicity of …

Importance Ototoxicity is an irreversible direct and late effect of certain childhood cancer
treatments. Audiologic surveillance during therapy as part of the supportive care pathway …

Background Irreversible sensorineural hearing loss is a common side effect of platinum
treatment with the potential to significantly impair the neurocognitive, social and educational …

The goals of the Association for Molecular Pathology Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …